Merck KGaA lifts FY guidance on surging demand for lab supplies

This post was originally published on this site

In an unscheduled statement, the diversified group said it now expects 2021 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, to reach 6 billion to 6.3 billion euros ($7 billion to $7.3 billion), up from 5.2 billion in 2020.

It had previously targeted 5.6 billion to 6 billion euros.

($1 = 0.8633 euros)